Research programme: cancer therapeutics - Galapagos NV

Drug Profile

Research programme: cancer therapeutics - Galapagos NV

Alternative Names: '1790 - Galapagos NV; GLPG 1790; Triple-negative breast cancer therapy - Galapagos NV

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Class Small molecules
  • Mechanism of Action EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Malignant melanoma

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in Belgium
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Belgium (PO)
  • 18 Mar 2014 Pharmacodynamics and adverse events data from a preclinical trial in triple-negative Breast cancer released by Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top